Lorus Therapeutics (NASDAQ:APTO) (TSE:APS) has been assigned a $6.00 target price by equities research analysts at Roth Capital in a research report issued to clients and investors on Monday. The brokerage currently has a “buy” rating on the biotechnology company’s stock. Roth Capital’s price objective indicates a potential upside of 67.13% from the company’s current price.
APTO has been the subject of several other research reports. HC Wainwright set a $6.00 price target on shares of Lorus Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, March 28th. Zacks Investment Research raised shares of Lorus Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, February 13th. Finally, ValuEngine cut shares of Lorus Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Thursday, March 1st. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $5.63.
Shares of APTO traded up $0.30 during mid-day trading on Monday, hitting $3.59. The company’s stock had a trading volume of 771,854 shares, compared to its average volume of 422,159. Lorus Therapeutics has a 52-week low of $0.78 and a 52-week high of $3.97. The stock has a market capitalization of $101.01, a PE ratio of -6.90 and a beta of 2.32.
Lorus Therapeutics Company Profile
Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.
Receive News & Ratings for Lorus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lorus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.